Ocugen, Inc.
OCGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001372299
In the last 90 days, Ocugen, Inc. insiders filed 0 open-market purchases and 1 sale; 147 institutions reported holding it in 13F filings for Q2 2026, worth $222.1M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Ocugen, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 109
- +16 vs. Q3 2025
- Shares held
- 60.8M
- +15.1M (+33.1%) vs. Q3 2025
- Total value
- $82.2M
- +$7.68M (+10.3%) vs. Q3 2025
- New holders
- 30
- 32 more added
- Sold out
- 14
- 18 more reduced
4 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting OCGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 147 | $222.1M |
| Q1 2026 | 137 | $200.5M |
| Q4 2025 | 109 | $82.2M |
| Q3 2025 | 97 | $74.8M |
| Q2 2025 | 104 | $50.1M |
| Q1 2025 | 110 | $54.2M |
| Q4 2024 | 114 | $57.7M |
| Q3 2024 | 115 | $79.1M |
| Q2 2024 | 101 | $104.4M |
| Q1 2024 | 81 | $54.0M |
| Q4 2023 | 68 | $15.1M |
| Q3 2023 | 78 | $13.2M |
| Q2 2023 | 96 | $26.5M |
| Q1 2023 | 103 | $53.2M |
| Q4 2022 | 114 | $117.0M |
| Q3 2022 | 128 | $146.5M |
| Q2 2022 | 124 | $193.1M |
| Q1 2022 | 122 | $279.2M |
| Q4 2021 | 122 | $291.2M |
| Q3 2021 | 116 | $396.4M |
| Q2 2021 | 129 | $455.7M |
| Q1 2021 | 82 | $167.3M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Ocugen, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 1,700,400 | $2.30M | 0.00% | +1,410,200+485.9% | Added |
| Goldman Sachs Group Inc | 2,302,475 | $3.11M | 0.00% | +2,204,765+2,256.4% | Added |
| Marshall Wace, LLP | 2,530,956 | $3.42M | 0.00% | +2,530,956 | New |
| Geode Capital Management, LLC | 3,819,242 | $5.16M | 0.00% | +142,050+3.9% | Added |
| State Street Corp | 3,978,738 | $5.37M | 0.00% | +2,623,361+193.6% | Added |
| BlackRock, Inc. | 4,556,544 | $6.15M | 0.00% | +502,086+12.4% | Added |
| UBS Group AG | 4,849,353 | $6.55M | 0.00% | +3,824,474+373.2% | Added |
| Millennium Management LLC | 5,396,417 | $7.29M | 0.01% | +1,234,268+29.7% | Added |
| Vanguard Group Inc | 16,475,562 | $22.2M | 0.00% | +1,251,977+8.2% | Added |
| GMT Capital Corp | 0 | $0 | 0.00% | −4,153,798−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −374,514−100.0% | Sold out |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −302,371−100.0% | Sold out |
| SummitTX Capital, L.P. | 0 | $0 | 0.00% | −197,238−100.0% | Sold out |
| Scientech Research LLC | 0 | $0 | 0.00% | −105,005−100.0% | Sold out |
| Invesco Ltd. | 0 | $0 | 0.00% | −45,061−100.0% | Sold out |
| Baader Bank INC | 0 | $0 | 0.00% | −34,792−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −11,540−100.0% | Sold out |
| Gainplan LLC | 0 | $0 | 0.00% | −11,325−100.0% | Sold out |
| Envestnet Asset Management Inc | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Flagship Harbor Advisors, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Jones Financial Companies LLLP | 0 | $0 | 0.00% | −475−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −270−100.0% | Sold out |
| Ancora Advisors, LLC | 0 | $0 | 0.00% | −140−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | – | – | – | – | Not filed |
| Cubist Systematic Strategies, LLC | – | – | – | – | Not filed |
| Point72 Europe (London) LLP | – | – | – | – | Not filed |
| Point72 (DIFC) Ltd | – | – | – | – | Not filed |